FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

	tion 1(b).		Filed		suant to Se Section 30											uis pei i	esponse:	0.5	
Name and Address of Reporting Person* Tanimoto Sarina					2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
(Last) (First) (Middle) C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 120				04	3. Date of Earliest Transaction (Month/Day/Year) 04/16/2024 4. If Amendment - Date of Original Filed (Month/Day/Year)									X Officer (give title Other (specify below) below) CHIEF MEDICAL OFFICER					
(Street) SAN DIEGO CA 92130				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication															
					X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - Non-Deriva	tive	e Securi	ties	Acqu	ired	, Dis	posed	of, or	Benefi	cial	ly Own	ed				
Date		2. Transaction Date (Month/Day/Yea	r) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)						Beneficially Owned Following		s Illy J	Form:		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Am	ount	(A) or (D)	Price		Reported Transacti (Instr. 3 a	on(s)				
Common	Stock			\perp										3,276	,854	I)		
Common	Stock		04/16/2024				S		50	1,000 ⁽¹⁾	D	\$9.280	4 ⁽²⁾	1,647	,447		I	By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 ⁽³⁾	
Common	Stock		04/16/2024				S		50	,000(1)	D	\$9.279	7 ⁽⁴⁾	1,848	,499		I	By Lowenthal- Tanimoto Family Trust U/A DTD 4/3/2006 ⁽⁵⁾	
Common Stock													1,646	,494		I	By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 ⁽⁶⁾		
Common	Stock													4,126	,822		I	By Spouse	
		Tal	ble II - Derivati											/ Owned	d				
1. Title of Derivative Security (Instr. 3)	ttle of 2. 3. Transaction 3A. Deemed Execution Date, urity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8) 5. Nun of Deriva Securi Acquir (A) or Dispos of (D) (Instr. and 5)		nber et ities red sed 3, 4	. Date	Exerc	S, CONVERTIE Exercisable and on Date Day/Year)				8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)			
				Cod		(A))ate	sable	Expiration Date	on Title	or Numbe of	r						

Explanation of Responses:

- $1.\ The\ shares\ were\ sold\ pursuant\ to\ a\ Rule\ 10b5-1\ trading\ plan\ entered\ into\ on\ March\ 31,\ 2023.$
- 2. The weighted average sales price for the transaction report was \$9.2804,and the range of prices were between \$9.05 and \$9.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.

3. The Reporting Person is trustee of the trust.

- 4. The weighted average sales price for the transaction report was \$9.2797, and the range of prices were between \$9.05 and \$9.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
- 5. The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
- 6. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

/s/ Kathleen Scott, Attorneyin-Fact 04/17/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.